NCT06154330 is a clinical trial in Glaucoma, Open-Angle, sponsored by Davinci LTD.

Who is sponsoring NCT06154330?

NCT06154330 is sponsored by Davinci LTD.

What condition does NCT06154330 study?

NCT06154330 studies Glaucoma, Open-Angle, Suprachoroidal Space, Pseudo Exfoliation Syndrome.

Is NCT06154330 still recruiting?

NCT06154330 is currently status unknown. Last updated 4 December 2023.

Last reviewed 2023-12-04 · How we verify

NCT06154330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Suprachoroidal Tube Shunt in Patients With Primary Open and Pseudoexfoliation Glaucomas

Status unknown Last updated 4 December 2023

What this trial tests

trial in Glaucoma, Open-Angle in 91 participants. Status unknown.

Timeline

20 November 2023

Primary endpoint
20 December 2023

23 December 2023

Quick facts

Lead sponsor	Davinci LTD
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	91
Start date	20 November 2023
Primary completion	20 December 2023
Estimated completion	23 December 2023
Sites	1 location across Georgia

Conditions studied

Glaucoma, Open-Angle — all drugs for Glaucoma, Open-Angle →
Suprachoroidal Space — all drugs for Suprachoroidal Space →
Pseudo Exfoliation Syndrome — all drugs for Pseudo Exfoliation Syndrome →

Sponsor

Davinci LTD

Who can join

Adults 40 to 90, any sex, with Glaucoma, Open-Angle or Suprachoroidal Space. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess safety and efficacy of a novel suprachoroidal silicone tube (SST) shunt for the treatment of primary open angle and exfoliative glaucomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glaucoma, Open-Angle

Currently open trials in the same condition.

NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension · Phase 2 · recruiting
NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma · NA · recruiting
NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial · Phase 3 · recruiting
NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma · Phase 3 · recruiting
NCT06058598 — Exercise Training in Patients With Glaucoma · NA · active not recruiting

Other Davinci LTD trials

Trials by the same sponsor.

NCT06691555 — Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06154330 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Davinci LTD
Last refreshed: 4 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06154330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing